Court Place Advisors LLC Takes $340,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Court Place Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 5,500 shares of the company’s stock, valued at approximately $340,000.

Other large investors also recently modified their holdings of the company. Shaker Investments LLC OH increased its holdings in shares of Amphastar Pharmaceuticals by 136.0% in the 4th quarter. Shaker Investments LLC OH now owns 49,078 shares of the company’s stock valued at $3,035,000 after acquiring an additional 28,283 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 44.8% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company’s stock valued at $25,518,000 after acquiring an additional 171,642 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $1,833,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Amphastar Pharmaceuticals by 7.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 352,378 shares of the company’s stock valued at $16,206,000 after acquiring an additional 24,116 shares during the last quarter. Finally, Rafferty Asset Management LLC bought a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at approximately $205,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 500 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the sale, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the completion of the sale, the director now owns 80,333 shares in the company, valued at approximately $4,265,682.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares of the company’s stock, valued at approximately $1,006,160.68. The disclosure for this sale can be found here. Insiders sold a total of 14,000 shares of company stock worth $660,860 in the last 90 days. 27.80% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Stock Down 2.1 %

Shares of AMPH traded down $0.85 during trading hours on Wednesday, hitting $40.05. 494,596 shares of the company were exchanged, compared to its average volume of 466,300. The company has a market cap of $1.96 billion, a PE ratio of 15.52, a PEG ratio of 0.97 and a beta of 0.84. The firm’s 50 day moving average is $46.59 and its 200-day moving average is $51.23. Amphastar Pharmaceuticals, Inc. has a 52 week low of $35.62 and a 52 week high of $67.66. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.70 and a current ratio of 2.17.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). The company had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. On average, equities research analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. JPMorgan Chase & Co. assumed coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective for the company. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.